TILT Biotherapeutics Oy is led by a highly experienced team with decades of expertise in early-stage cancer therapeutics research and development. Based in Finland, the company also operates a wholly owned U.S. subsidiary and has established a dedicated transition team to drive the later-stage development of its lead asset, TILT-123.
Tiltbio USA
The U.S. team contributes complimentary industry expertise from both Europe and the United States to drive the progression of the lead asset into late-stage development.
These are the principles that guide our work:
Board of Directors
The Board includes leading authorities and serial entrepreneurs in the life sciences, legal, financial, and pharmaceutical fields. The board is chaired by Tuija Keinonen (PhD, Profesor of Practice).
Tuija Keinonen
Pharm PhD, Professor of Practice, Chair of the Board of Directors, Advisor - Operational Excellence
Scientific Advisors
Tiltbio’s scientific and clinical advisors include prominent clinicians and researchers from cancer-focused institutions across Europe and the U.S. In addition, the company holds indication specific advisory boards.
